Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses And Other Current Liabilities

Accrued Expenses And Other Current Liabilities

9 Months Ended

Sep. 30, 2019

Accrued Liabilities and Other Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of September 30, 2019 and December 31, 2018 consisted of the following:



	As of
	September 30, 2019		December 31, 2018
Sales returns and allowances	$	5,143,150	$	3,972,510
Medicaid rebates	2,603,632		2,237,269
Minimum sales commitments, royalties payable, and purchase obligations	957,243		9,662,901
Compensation and benefits	1,993,211		1,953,065
Research and development expenses	1,409,738		278,132
Sales and marketing	125,494		1,112,378
General and administrative	775,163		235,721
Other	126,264		279,397
Total accrued expenses and other current liabilities	$	13,133,895	$	19,731,373

As detailed in Note 14, in connection with the Company entering into the Aytu transaction in October 2019, Aytu assumed certain of the Company's liabilities including certain accrued expenses and other current liabilities primarily related to sales returns and Medicaid rebates, upon closing of the transaction on November 1, 2019. However, accrued expenses and other current liabilities as of September 30, 2019 do not factor in Aytu's assumption of such liabilities because the transaction occurred subsequent to quarter end.